Jump to content

Sulfinpyrazone: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Undid revision 722852607 by 79.74.20.70 (talk) revert unsourced observation by sock of blocked user Nuklear
 
(14 intermediate revisions by 10 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
{{Drugbox
| verifiedrevid = 470473641
| verifiedrevid = 470473641
Line 4: Line 6:
| image = Sulfinpyrazone.svg
| image = Sulfinpyrazone.svg
<!--Clinical data-->
<!--Clinical data-->
| tradename = Apo-sulfinpyrazone
| tradename = Anturan, Anturane, Apo-sulfinpyrazone
| Drugs.com = {{drugs.com|monograph|sulfinpyrazone}}
| Drugs.com = {{drugs.com|monograph|sulfinpyrazone}}
| MedlinePlus = a682339
| MedlinePlus = a682339
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_category =
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =
| legal_status =
| routes_of_administration = oral intravenous
| routes_of_administration = [[Oral administration|By mouth]] intravenous
<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
| protein_bound = 98–99%
| protein_bound = 98–99%
| metabolism = hepatic
| metabolism = liver
| elimination_half-life =
| elimination_half-life =
| excretion = renal
| excretion = kidney
<!--Identifiers-->
<!--Identifiers-->
| IUPHAR_ligand = 5826
| IUPHAR_ligand = 5826
Line 27: Line 28:
| ATC_prefix = M04
| ATC_prefix = M04
| ATC_suffix = AB02
| ATC_suffix = AB02
| ATC_supplemental =
| ATC_supplemental =
| PubChem = 5342
| PubChem = 5342
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
Line 43: Line 44:
<!--Chemical data-->
<!--Chemical data-->
| C=23 | H=20 | N=2 | O=3 | S=1
| C=23 | H=20 | N=2 | O=3 | S=1
| molecular_weight = 404.48 g/mol
| smiles = O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
| smiles = O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
Line 51: Line 51:
}}
}}


'''Sulfinpyrazone''' is a [[uricosuric]] [[medication]] used to treat [[gout]]. It also sometimes is used to reduce [[platelet]] aggregation by inhibiting [[degranulation]] of platelets which reduces the release of [[Adenosine diphosphate|ADP]] and [[thromboxane]].
'''Sulfinpyrazone''' is a [[uricosuric]] [[medication]] used to treat [[gout]]. It also sometimes is used to reduce [[platelet]] aggregation by inhibiting [[degranulation]] of platelets which reduces the release of [[Adenosine diphosphate|ADP]] and [[thromboxane]].


Like other uricosurics, sulfinpyrazone works by competitively inhibiting [[uric acid]] reabsorption in the [[proximal tubule]] of the [[kidney]].
Like other uricosurics, sulfinpyrazone works by competitively inhibiting [[uric acid]] reabsorption in the [[proximal tubule]] of the [[kidney]].


__TOC__
==Contraindications==
==Contraindications==
Sulfinpyrazone must not be used in persons with [[renal impairment]] or a high rate of excretion of uric acid ([[hyperuricosuria]]).<ref name="pmid16740561">{{cite journal |author=Underwood M |title=Diagnosis and management of gout |journal=BMJ |volume=332 |issue=7553 |pages=1315–9 |date=June 2006 |pmid=16740561 |pmc=1473078 |doi=10.1136/bmj.332.7553.1315 |url=}}</ref>
Sulfinpyrazone must not be used in persons with [[renal impairment]] or a history of uric acid kidney stones.<ref name="pmid16740561">{{cite journal | vauthors = Underwood M | title = Diagnosis and management of gout | journal = BMJ | volume = 332 | issue = 7553 | pages = 1315–9 | date = June 2006 | pmid = 16740561 | pmc = 1473078 | doi = 10.1136/bmj.332.7553.1315 }}</ref>


==References==
== Research ==
Trial have found that, '''Sulfinpyrazone''' taken in specific daily dose immediately following a patient having suffered from a [[myocardial infarction]] seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their '''heart attack'''. <ref>{{Cite journal|date=1980-01-31|title=Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction|url=https://doi.org/10.1056/NEJM198001313020502|journal=New England Journal of Medicine|volume=302|issue=5|pages=250–256|doi=10.1056/NEJM198001313020502|issn=0028-4793|pmid=6985706 |author1=Anturane Reinfarction Trial Research Group }}</ref>

== References ==
{{reflist}}
{{reflist}}


Line 66: Line 70:
[[Category:Antigout agents]]
[[Category:Antigout agents]]
[[Category:Pyrazolidindiones]]
[[Category:Pyrazolidindiones]]



{{musculoskeletal-drug-stub}}
{{musculoskeletal-drug-stub}}

Latest revision as of 12:39, 30 November 2024

Sulfinpyrazone
Clinical data
Trade namesAnturan, Anturane, Apo-sulfinpyrazone
AHFS/Drugs.comMonograph
MedlinePlusa682339
Routes of
administration		By mouth intravenous
ATC code
Pharmacokinetic data
Protein binding98–99%
Metabolismliver
Excretionkidney
Identifiers
  • 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.325 Edit this at Wikidata
Chemical and physical data
FormulaC23H20N2O3S
Molar mass404.48 g·mol−1
3D model (JSmol)
  • O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
  • InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 checkY
  • Key:MBGGBVCUIVRRBF-UHFFFAOYSA-N checkY
  (verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications

[edit]

Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]

Research

[edit]

Trial have found that, Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack. [2]

References

[edit]
  1. ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
  2. ^ Anturane Reinfarction Trial Research Group (1980-01-31). "Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction". New England Journal of Medicine. 302 (5): 250–256. doi:10.1056/NEJM198001313020502. ISSN 0028-4793. PMID 6985706.
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Sulfinpyrazone&oldid=1260379889"